

7/14 amended
USSN - 09/987,107

subcutaneously, intradermally, intratechally, through the buccal-, anal-, vaginal-, conjunctival-, or intranasal tissue, by inoculation into tissue, by an implant, or orally.

71 (amended). The method of claim 69, comprising administering to an individual a composition comprising at least 50 mg apolipoprotein construct per week.

72 (amended). The method of claim 69, comprising administration during at least 2 days.

73 (amended). The method of claim 69, comprising administering at least 10 mg/kg body weight.

81 (amended). The method of claim 69, when used in the treatment of arterial stenoses, claudicatio, carotis stenosis or cerebral arterial stenosis.

82 (amended). A method for treating a patient having a condition related to cholesterol, phospholipids and triacylglycerides LDL and HDL disorders, or arteriosclerotic diseases comprising transfecting at least one cell population with a nucleic acid sequence as defined in claim 63.

REMARKS

The present amendment conforms the claims to U.S. practice.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms

G:\BN\H\hoib\Graversen1a\graversen1.ptopreamend.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 2, 10, 14, 32, 33, 36, 37, 39, 43, 50, 53, 58, 62, 64, 68, 70, 71, 72, 73, 81 and 82 have been amended as follows:

2 (amended). The composition of claim 1, further comprising a spacer between the apo-A component and X, wherein the spacer comprises a spacer peptide comprising at least two amino acids[, such as at least three amino acids, for example at least five amino acids, such as at least ten amino acids, for example at least 15 amino acids, such as at least 20 amino acids, for example at least 30 amino acids, such as at least 40 amino acids, for example at least 50 amino acids, such as at least 60 amino acids, for example at least 70 amino acids, such as at least 80 amino acids, such as at least 90 amino acids such as approximately 100 amino acids].

10 (amended). The composition of claim 7, wherein the protein comprises at least one protein selected from the group comprising albumin, [more preferably serum albumin,] the serine protease fragment of plasminogen or another serine protease engineered to be inactive by disruption of the catalytic triad, and the constant region of the heavy chain of immunoglobulins.

14 (amended). The composition of claim 7, wherein the peptide constituting the component X comprises [more than 1] at least two amino acids [such as more than 2 amino acids, for example more than 5 amino acids, such as more than 10 amino acids, for example more than 15 amino acids, such as more than 20 amino acids, such as more than 30 amino acids, for example more than 40 amino acids, such as more than 50 amino acids, for example more than 75 amino acids, such as more than 100 amino acids, for example more than 200 amino acids, such as more than 300 amino acids, for example more than 400 amino acids, such as more than 500 amino acids, for example more than 600 amino acids, such as more than 700 amino acids, for example more than 800 amino acids, such as more than 900 amino acids, for example more than 1000, 1250, 1500, 2000, or 2500 amino acids.].

32 (amended). The composition of claim 1, having a half-life [of] at least 2 times the half-life of native Apo A-I, A-II or A-IV[, preferably at least 2 times higher, more preferably at least 3 times higher such as 4 times, more preferably at least 5 times higher, such as 6 times, more preferably at least 8 times higher such as at least 10 times].

33 (amended). The composition of claim 1, capable of binding to a receptor selected from the group consisting of cubilin, Scavenger receptor class B, type 1 (SR-B1), ATP-binding cassette 1 (ABC1), Lecithin:cholesterol acyltransferase (LCAT), Cholesteryl-ester transfer protein (CETP), and Phospholipid transfer protein (PLTP).

36 (amended). The composition according to claim 1, said construct comprising [having] an amino acid sequence having [sharing] at least 70% sequence [identify] identity to one of the sequences SEQ ID NO 3 to SEQ ID NO 11, or SEQ ID NO 14.

37 (amended). The composition of claim 1, further comprising pharmaceutical acceptable excipients, adjuvants, or additives[, such as phospholipids, cholesterol, or triglycerides].

39 (amended). The construct of claim 38, further comprising a spacer peptide between the apo-A component and X, wherein the spacer peptide comprises at least two amino acids[, such as at least three amino acids, for example at least five amino acids, such as at least ten amino acids, for example at least 15 amino acids, such as at least 20 amino acids, for example at least 30 amino acids, such as at least 40 amino acids, for example at least 50 amino acids, such as at least 60 amino acids, for example at least 70 amino acids, such as at least 80 amino acids, such as at least 90 amino acids such as approximately 100 amino acids].

43 (amended). The construct according to claim 38, wherein component X comprises at least one [amphipatic] amphipathic helix containing apolipoprotein.

50 (amended). The construct of claim 38, wherein the oligomerising module is of non-peptide nature[, such as a nucleic

USSN - 09/987,107

acid sequence comprising a DNA, a RNA, a PNA, or a LNA sequence.].

53 (amended). The construct of claim [the claims] 52, wherein the stable complex comprises [includes] a coiled coil structure.

58 (amended). The construct of claim 57, wherein the [cystein] cysteine residue no. 50 is substituted by a serine residue, a threonine residue, or a methionine residue.

62 (amended). The construct according to claim 38, comprising [having] an amino acid sequence having [sharing] at least 70% sequence identity to at least one of the sequences SEQ ID NO 3 to SEQ ID NO 11, or SEQ ID NO 14.

64 (amended). Nucleic acid according to claim 63, encoding an amino acid sequence having [sharing] at least 70% amino acid sequence identity to any of SEQ ID NO 2 to SEQ ID NO 11 or SEQ ID NO 14[, preferably to any of SEQ ID NO 3 to SEQ ID NO 11, or SEQ ID NO 14].

68 (amended). A method for the production of an apolipoprotein construct as defined in [the claims] claim 1, comprising the steps of:

- culturing a transformed host cell under conditions promoting the expression of a protein construct according to [claims] claim 1, and
- obtaining and recovering said protein construct[,
- optionally, further processing said protein construct].

70 (amended). The method of claim 69, wherein the pharmaceutical composition is administered intravenously, intraarterially, intramuscularly, transdermally, pulmonary, subcutaneously, intradermally, intratechally, through the buccal-, anal-, vaginal-, conjunctival-, or intranasal tissue, [or] by inoculation into tissue, [such as tumour tissue, or] by an implant, or orally.

71 (amended). The method of claim 69, comprising administering to an individual a composition comprising at least 50 mg apolipoprotein construct per week[, preferably at least at

USSN - 09/987,107

least 100 mg/week, for example at least 250 mg/week, such as at least 500 mg/week, for example at least 750 mg/week such as at least 1000 mg/week, for example at least 1250 mg/week, such as at least 1500 mg/week, for example at least 2000 mg/week, such as at least 2500 mg/week, for example at least 5000 mg/week].

72 (amended). The method of claim 69, comprising administration during [1, 2, 3, 4, 5, 6, 7, 8 or up to 10] at least 2 days.

73 (amended). The method of claim 69, comprising administering at least 10 mg/kg body weight[, such as at least 20 mg/kg body weight, for example at least 30 mg/kg, such as at least 40 mg/kg, for example at least 50 mg/kg, such as at least 60 mg/kg, for example at least 70 mg/kg, such as at least 75 mg/kg, for example at least 90 mg/kg, such as at least 100 mg/kg, for example at least 125 mg/kg, such as at least 150 mg/kg, for example at least 200 mg/kg, such as at least 250 mg/kg, for example at least 300 mg/kg, such as at least 400 mg/kg, for example at least 500 mg/kg, such as at least 600 mg/kg, for example at least 700 mg/kg, such as at least 800 mg/kg, for example at least 900 mg/kg, such as at least 1000 mg/kg].

81 (amended). The method of claim 69, when used in the treatment of arterial stenoses, [such as] claudicatio, carotis stenosis or cerebral arterial stenosis.

82 (amended). A method for treating a patient having a condition related to cholesterol, phospholipids and triacylglycerides LDL and HDL disorders, [and] or arteriosclerotic diseases comprising transfecting at least one cell population with a nucleic acid sequence as defined in claim [the claims] 63.